Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Journal of Thoracic Oncology.
Times cited: 5
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer.
Clinical Cancer Research.
Times cited: 6